---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015993"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:13:17.411771+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ocugen receives Nasdaq bid price deficiency notice and reports Q1 net loss of $0.07 per share

## Summary
- Nasdaq notified Ocugen on May 1 that its stock closed below $1.00 for 30 consecutive days; 180-day cure period until Oct 30, 2023.
- Cash and investments $76.7M at March 31, 2023, down from $90.9M at Dec 31, 2022; funding expected into Q1 2024.
- Net loss per share $0.07 in Q1 2023 vs $0.09 in Q1 2022; total operating expenses $17.8M.
- OCU400 Phase 1/2 shows positive preliminary efficacy/safety; FDA approved pediatric enrollment; Phase 3 trial planned late 2023.
- COVAXIN development in North America discontinued; shift to inhaled mucosal vaccine platform (flu and COVID-19).

## SEC filing metadata
- accession: 0001628280-23-015993
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/0001628280-23-015993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/ocgn-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015993
- JSON: https://secwatch.observer/filing/0001628280-23-015993.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015993.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported the three months ended March 31, 2023 results: EPS $0.07 net loss per common share.
  - Period: the three months ended March 31, 2023
  - EPS: $0.07 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.07 net loss per common share for the three months ended March 31, 2023 compared to a $0.09 net loss per common share for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/0001628280-23-015993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.